New targeted drug shows promise for Hard-to-Treat cancers
Disease control
Completed
This study tested a new drug called JAB-21822, alone or with another drug (cetuximab), in 29 adults with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal was to check safety and how well the drug works. Participants had already tried at least one st…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC